Immunomedics Provides Clinical Updates on Subcutaneous Injections of ... MarketWatch (press release) The complementarity-determining regions (CDRs) of veltuzumab are identical to rituximab, except for one amino acid residue, which appears to give veltuzumab some unique properties. In an animal model of human lymphoma, veltuzumab demonstrated ... |
